BACKGROUND: Cell-free DNA reflects both normal and tumor-derived DNA released into the circulation through cellular necrosis and apoptosis. The authors sought to determine the role of preoperative total plasma cell-free DNA levels in predicting clinical outcome in patients with ovarian cancer. METHODS: After institutional review board consent, DNA was extracted from plasma of 164 women with invasive epithelial ovarian carcinoma (EOC), 49 with benign ovarian neoplasms, and 75 age-matched controls. The samples were randomly divided into training (n = 144) and validation (n = 144) sets. Quantification of cell-free DNA was performed using real-time polymerase chain reaction for beta-globin, and the number of genome equivalents (GE) per milliliter of plasma was determined. Cell-free DNA was correlated with clinicopathologic parameters. RESULTS: The training and validation sets were similar in terms of demographic features. In the training set, EOC patients had a median preoperative cell-free DNA level of 10,113 GE/mL, compared with patients with benign ovarian neoplasms (median, 2365 GE/mL; P < .0001) and controls (median, 1912 GE/mL, P < .0001). Cell-free DNA >22,000 GE/mL was significantly associated with decreased patient survival (P < .001). After adjusting for other clinical variables, preoperative cell-free DNA >22,000 GE/mL was an independent predictor (P = .02) for disease-specific survival. Analysis of the validation set confirmed significantly higher cell-free DNA levels in EOC (median, 13,672 GE/mL) and that cell-free DNA >22,000 GE/mL was associated with a 2.83-fold increased risk of death from disease (P < .001). CONCLUSIONS: Preoperative plasma total cell-free DNA levels are significantly elevated in patients with EOC. Elevated plasma cell-free DNA is an independent predictor for death from disease in ovarian cancer. (c) 2010 American Cancer Society.
BACKGROUND: Cell-free DNA reflects both normal and tumor-derived DNA released into the circulation through cellular necrosis and apoptosis. The authors sought to determine the role of preoperative total plasma cell-free DNA levels in predicting clinical outcome in patients with ovarian cancer. METHODS: After institutional review board consent, DNA was extracted from plasma of 164 women with invasive epithelial ovarian carcinoma (EOC), 49 with benign ovarian neoplasms, and 75 age-matched controls. The samples were randomly divided into training (n = 144) and validation (n = 144) sets. Quantification of cell-free DNA was performed using real-time polymerase chain reaction for beta-globin, and the number of genome equivalents (GE) per milliliter of plasma was determined. Cell-free DNA was correlated with clinicopathologic parameters. RESULTS: The training and validation sets were similar in terms of demographic features. In the training set, EOC patients had a median preoperative cell-free DNA level of 10,113 GE/mL, compared with patients with benign ovarian neoplasms (median, 2365 GE/mL; P < .0001) and controls (median, 1912 GE/mL, P < .0001). Cell-free DNA >22,000 GE/mL was significantly associated with decreased patient survival (P < .001). After adjusting for other clinical variables, preoperative cell-free DNA >22,000 GE/mL was an independent predictor (P = .02) for disease-specific survival. Analysis of the validation set confirmed significantly higher cell-free DNA levels in EOC (median, 13,672 GE/mL) and that cell-free DNA >22,000 GE/mL was associated with a 2.83-fold increased risk of death from disease (P < .001). CONCLUSIONS: Preoperative plasma total cell-free DNA levels are significantly elevated in patients with EOC. Elevated plasma cell-free DNA is an independent predictor for death from disease in ovarian cancer. (c) 2010 American Cancer Society.
Authors: Y M Lo; M S Tein; T K Lau; C J Haines; T N Leung; P M Poon; J S Wainscoat; P J Johnson; A M Chang; N M Hjelm Journal: Am J Hum Genet Date: 1998-04 Impact factor: 11.025
Authors: Aparna A Kamat; Farideh Z Bischoff; Dianne Dang; Matthew F Baldwin; Liz Y Han; Yvonne G Lin; William M Merritt; Charles N Landen; Chunhua Lu; David M Gershenson; Joe L Simpson; Anil K Sood Journal: Cancer Biol Ther Date: 2006-10-26 Impact factor: 4.742
Authors: Oliver Gautschi; Colette Bigosch; Barbara Huegli; Monika Jermann; Arthur Marx; Eveline Chassé; Daniel Ratschiller; Walter Weder; Markus Joerger; Daniel C Betticher; Rolf A Stahel; Annemarie Ziegler Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544
Authors: William I Wei; Anthony P W Yuen; Raymond W M Ng; W K Ho; Dora L W Kwong; Jonathan S T Sham Journal: Head Neck Date: 2004-10 Impact factor: 3.147
Authors: Hsueh-Wei Chang; Shing M Lee; Steven N Goodman; Gad Singer; Sarah K R Cho; Lori J Sokoll; Fredrick J Montz; Richard Roden; Zhen Zhang; Daniel W Chan; Robert J Kurman; Ie-Ming Shih Journal: J Natl Cancer Inst Date: 2002-11-20 Impact factor: 13.506
Authors: Aadel A Chaudhuri; Michael S Binkley; Evan C Osmundson; Ash A Alizadeh; Maximilian Diehn Journal: Semin Radiat Oncol Date: 2015-05-15 Impact factor: 5.934